Ticker Details
Celldex Therapeutics, Inc. Celldex Therapeutics Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
IPO Date:	March 26, 1990
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.53B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.44 | 3.04%
Avg Daily Range (30 D):	$0.55 | 2.22%
Avg Daily Range (90 D):	$0.57 | 2.23%

Institutional Daily Volume
Avg Daily Volume:	.45M
Avg Daily Volume (30 D):	.53M
Avg Daily Volume (90 D):	.61M

Trade Size
Avg Trade Size (Sh.):	64
Avg Trade Size (Sh.) (30 D):	56
Avg Trade Size (Sh.) (90 D):	55

Institutional Trades
Total Institutional Trades:	4,734
Avg Institutional Trade:	$2.1M
Avg Institutional Trade (30 D):	$1.92M
Avg Institutional Trade (90 D):	$2.21M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.85M
Avg Closing Trade (30 D):	$2.31M
Avg Closing Trade (90 D):	$2.8M
Avg Closing Volume:	78.3K

News

Aug 27, 2025 @ 8:50 AM Chronic Inducible Urticaria (CIndU) Market Researc... Source: Researchandmarkets.Com

Jun 14, 2025 @ 2:48 PM Celldex Presents Data Demonstrating Profound Long ... Source: N/A

Mar 3, 2025 @ 1:01 PM Celldex Therapeutics Presents Positive Preclinical... Source: N/A

Mar 1, 2025 @ 5:45 PM Celldex Therapeutics Presents Positive Results fro... Source: N/A

Feb 20, 2025 @ 6:00 PM Chronic Spontaneous Urticaria Market to Register I... Source: Delveinsight

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-3.38	$-1.01	$-.85
Diluted EPS	$-3.38	$-1.01	$-.85
Revenue	$2.6M	$M	$.73M
Gross Profit
Net Income / Loss	$-224.53M	$-67.04M	$-56.6M
Operating Income / Loss	$-256.24M	$-73.62M	$-63.86M
Cost of Revenue
Net Cash Flow	$-.36M	$12.99M	$5.91M
PE Ratio

Splits
Feb 11, 2019	1:15
Mar 10, 2008	1:12
Mar 07, 2008	1:12